Status:
ACTIVE_NOT_RECRUITING
Integrative Sequencing In Germline and Hereditary Tumours
Lead Sponsor:
University Health Network, Toronto
Conditions:
Hereditary Cancer Syndrome
High-Risk
Eligibility:
All Genders
18+ years
Brief Summary
This study will investigate the utility of integrative sequencing of individuals and families at risk of hereditary cancer syndromes and will uncover novel contributors to tumourigenesis. Integrative ...
Eligibility Criteria
Inclusion
- Patients must be ≥18 years of age
- All patients and enrolled family members must have a signed and dated informed consent form
- All individuals at risk of a hereditary cancer syndrome without a known germline mutation from clinical genetic testing, will be eligible for this study. This includes:
- Individuals with multiple primary malignancies
- Families with a strong family history of cancer suggestive of a hereditary cancer syndrome
- Young individuals with cancer (10 years earlier than the age of onset of sporadic cases) and no identified gene mutation
- Rare cancer histologies
- Individuals with an identified germline mutation will also be eligible for this study, if there are discordant family members suggesting additional genetic factors contributing to the variable familial phenotype. For example, a family composed of mutation carriers severely affected with cancers, and carriers unaffected with cancer.
Exclusion
- None.
Key Trial Info
Start Date :
October 2 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03857594
Start Date
October 2 2018
End Date
September 1 2026
Last Update
December 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network
Toronto, Ontario, Canada